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https://doi.org/10.1016/j.jtho.2019.05.038The primary health benefits of cancer screening are
realized by improved cancer-specific or overall mortal-
ity. Low-dose computed tomography (LDCT) screening is
a relatively recent addition to the repertoire of methods
that the health care system uses to improve mortality
from lung cancer.1 However, a recent analysis of the
benefits of health care on premature mortality shows
that the effects of behavioral factors far outweigh de-
ficiencies in health care access or delivery.2 The clinical
utility of LDCT is driven by smoking, which has a long
well-established history of causing a spectrum of
adverse health conditions resulting in a 10-year short-
ened life expectancy.3 Whereas smoking has decreased
in developed countries such as the United States over the
past 50 years, smoking worldwide has unfortunately
increased.1,4,5 Proven methods to curb smoking include
research, educational campaigns, taxation, and regula-
tory initiatives to enact broad-based smoking re-
strictions.4 Throughout, one emphasis has remained
constant: strategies that help tobacco users quit are
critical to reducing cancer and mortality from cancer and
other causes.6 It is not currently clear what smoking
cessation approaches are best in combination with
LDCT.7 Given the health benefits of quitting, behavioral
research on ways to maximize quit rates are needed.
In the accompanying article, Tremblay et al.8 report
that telephone-based smoking cessation counselling did
not improve quit rates in active smokers undergoing
LDCT screening. The study is an important contribution
for the oncology field and helps advance the research
agenda on smoking cessation in patients at high risk of
cancer. The authors randomized 345 active smokers
undergoing LDCT screening to receive a telephone
intervention (an “opt-out” approach where all patients
are contacted with an offer for smoking cessation ser-
vices) versus a mailed pamphlet containing contact in-
formation (an “opt-in” approach where patients must
independently seek services themselves). The primary
endpoint was self-reported 30-day abstinence at 12
months. Ultimately, 74% of patients randomized to the
telephone intervention completed at least one coun-
seling session (versus 7% of those randomized to mailedpamphlets), with 42% completing at least two. At 6
months, there was a trend toward increased current
(25.1% versus 17.2%, p ¼ 0.072) and 7-day abstinence
(23.3% versus 15.5%, p ¼ 0.065). However, the primary
endpoint of 30-day abstinence at 12 months was not
significantly different (14.0% versus 12.6%, p ¼ 0.704).
Although a “negative” study, results are thought-
provoking, and the authors are commended for their
efforts in conducting a rigorous randomized trial with
more than 300 participants.
The question remains as to why the primary objective
failed in a carefully conceived trial. The study certainly
has many strengths. The study’s parallel trial design
emulated a more real-world setting where patients
already enrolled in a screening study were randomized
regardless of quit motivation. Such an approach mini-
mizes the selection bias inherent in studies that enroll
patients willing to participate specifically in a smoking
cessation study. Study procedures appeared rigorous
with very few patients lost to follow-up (0.6%) for the
primary objective at 12 months. Results were also
similar to observed quit rates from other large LDCT
trials referenced by the authors. Even so, in addition to
the negative primary endpoint, there were no differences
in use of nicotine replacement therapy (NRT), pharma-
cologic aids, or even “intent to quit in the next 30 days”
between the intervention and control groups at 6, 12, or
24 months.
Several possibilities may help explain these find-
ings. Although LDCT screening is a convenient oppor-
tunity to contact patients, it may be particularly 
difficult to change behavior in this particular cohort. As 
the authors themselves acknowledge, “such partici-
pants are likely already thinking about their health, 
their cancer risk, and their tobacco habits, many (39%) 
had already tried to quit in the past year [and they have 
been] unable to quit despite widespread societal cues 
to quit, have failed previous attempts or were not 
necessarily seeking quitting assistance.” Strikingly, 
those with a history of cancer appeared less likely to 
quit smoking, possibly reflecting an established recal-
citrance to quitting. More intensive interventions, 
including in-person counseling, possibly family ther-
apy, and increased use of pharmacotherapy, may be 
needed in the face of the obstacles facing this particular 
patient population.
There were no differences in proximal endpoints 
such as use of NRT, pharmacologic aids, or “intent to 
quit” that could signal subsequent abstinence, raising 
concerns about the effectiveness of telephone interven-
tion. Patients randomized to intervention received their 
initial telephone call at a median of 16 days (range, 11–
21 days) after being informed of their LDCT screening 
results, and 26% did not receive any phone intervention 
as randomized. It is possible that intervention at, or 
closer to, the time of screening may have been more 
effective. Given that 86% of patients had a negative 
screening result, patients could feel relieved at being 
cleared of cancer and have even lower motivation to quit 
smoking when contacted several weeks later. This is in 
direct contrast to the cancer population, where bad news 
has just been delivered and potentially galvanizes action. 
It is encouraging, however, that patients who actually 
had one or more contacts with cessation counselors as 
randomized trended toward a higher 12-month absti-
nence rate (16.7% versus 6.7%, respectively, p ¼ 0.13). 
Differences in access to smoking aids such as NRT may 
also play an important role, with the relatively low use of 
NRT contributing to lower quit rates. Finally, the authors 
acknowledge the study was powered to detect a 13%
absolute improvement in quit rates, and it was under-
powered to detect smaller but still clinically significant 
differences.
A notable strength of the study by Tremblay et al.8 
was the opt-out strategy used in the intervention arm. 
This opt-out approach was innovative and showed the 
powerful ability to increase contact rates by providing 
smoking cessation counseling as the “default.” Opt-out 
approaches such as these have been proposed to be 
the standard of care when dealing with efforts targeting 
addiction and other high-risk behaviors.9 When applied 
to patients with cancer diagnoses, opt-out approachesshow consistently high participation rates, with subse-
quent reductions in mortality for lung cancer patients
who quit smoking.10-12 That the opt-out telephone
intervention was unsuccessful in this case may reflect
differences between screening and cancer populations.
Patients with cancer may have increased motivation for
behavioral change and more frequent contacts for
treatment, with more opportunities for counseling.
Screening patients, on the other hand, may have infre-
quent medical visits and less impetus to motivate
change. More research on the opt-out concept is clearly
needed to test innovative approaches for smoking
cessation in these settings. To this end, the National
Cancer Institute has formed the Smoking Cessation at
Lung Examination (SCALE) Collaboration.13 Funded
across eight projects, the SCALE Collaboration will
evaluate methods to provide smoking cessation using
quitlines, LDCT medical providers, and trained cessation
specialists across a variety of institutional and commu-
nity settings. Researchers will investigate intervention
type, intensity, timing, duration, and scale, in addition to
the use of telehealth, incentivization, and other behav-
ioral exercises.
Although Tremblay et al.8 did not find increased
abstinence with targeted phone interventions in the
context of LDCT screening, it is critical to retain
perspective on the magnitude of clinical benefit pro-
vided by smoking cessation. The financial and societal
effects of continued smoking are profound with annual
estimates of $1 trillion in economic damages interna-
tionally and nearly $300 billion in health care costs in
the United States alone.14 Long-term follow-up of
nearly 1 million people shows that current smoking
substantially increases mortality, but lung cancer
caused a relatively small percentage of deaths (7%),
comparable to stroke (7%) but less than 23% for
ischemic heart disease and 8% for other heart dis-
eases.6 LDCT in the absence of effective methods for
smoking cessation would appear to limit access to a
proven method to improve premature mortality. As
LDCT advances, efforts to reduce the burden of lung
cancer should be coupled with continued efforts to
reduce overall risks for premature mortality. Plenty of
room exists for improvement and progress, not only in
the setting of LDCT screening, but in general medicine
clinics, cancer hospitals, and society at large. Results
from Tremblay et al.8 assist in refining efforts to
improve smoking cessation in combination with LDCT
and support the need for continued investigation on
effective methods to improve overall health.
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